Lubrizol’s microencapsulated iron ingredient Lipofer outperforms conventional options in study

New research reveals that Lubrizol’s proprietary microencapsulated iron ingredient, Lipofer, “significantly outperforms” traditional forms of iron, like ferrous sulfate, ferrous bisglycinate, and other encapsulated iron salts.

As an orosoluble iron, Lipofer is a highly concentrated and micronized iron source designed specifically to reduce the associated side effects of iron supplementation while delivering a fully absorbable mineral that is “significantly easier and more pleasant to digest.”

The in vivo study in iron-deficient rats evaluated the ingredient’s bioavailability and gastrointestinal tolerability.

“The microencapsulation matrix we’ve developed ensures that iron is delivered in a controlled manner,” says Isabel Gómez, global marketing manager for Lubrizol Nutraceuticals. “This not only improves tolerability but also enhances the bioavailability of the mineral, as confirmed by the study’s haematological and biochemical markers.”

“This study reinforces our commitment to developing science-driven, consumer-preferred solutions that address real nutritional challenges. Iron deficiency continues to affect billions globally, and our microencapsulated iron ingredient offers a breakthrough in both efficacy and comfort.”

Stabilizing and sensory-enhancing

Lubrizol’s microencapsulation improves the sensory tolerance of iron supplementation by reducing the interactions between non-absorbed iron and gastrointestinal mucosa and possibly gut microbiota.

Lipofer microcapsules also contain lecithin, which helps the body absorb nutrients more effectively by integrating with the fats in cell membranes. Additionally, the tiny iron particles in Lipofer have a larger surface area that improves absorption and allows the iron to reach the intestine without causing side effects.

The Lipofer study, published in the peer-reviewed journal Nature, was designed and led by Roger Marineé-Casadó, Ph.D. It reveals the ingredient’s high level of effectiveness in reversing iron deficiency anemia within 14 days, while also being gentle on the stomach.

After three months of supplementation, Lipofer significantly boosted hemoglobin levels and improved the body’s iron stores, compared to the other iron sources. The rat group supplementing with Lipofer microcapsules had better systemic absorption, indicated by favorable changes in transferrin (the protein that carries iron in the blood), as well as in total iron-binding capacity.

No signs of gastrointestinal irritation

Even after prolonged administration, Lipofer-supplemented rats also showed no signs of gastrointestinal irritation or increased colon permeability in multiple assessments. This was concluded through the macroscopic examination of gut tissue, expression of the gut barrier’s mucus proteins, and inflammation-related signals.

In contrast, the ferrous sulfate supplement group exhibited inflammation, as shown by the increase in IL-6 — a key pro-inflammatory biomarker.

“These findings are a testament to the importance of formulation science in addressing micronutrient deficiencies,” says Alan Connolly, global R&D manager. “By improving both the absorption and the user experience with great-tasting iron supplements, we’re bridging the gap between clinical efficacy and consumer adherence.”

In a previous blind taste test involving 100 participants, consumers confirmed that Lipofer had a strong flavor appeal, with minimal metallic aftertaste.

Lubrizol’s microencapsulated iron delivered in pill form and as a powdered stick is water-dispersible, making it suitable for a comprehensive range of applications, including dietary supplement formats as well as functional foods and beverages. The company previously formulated it into a flavorful, pectin-based gummy.

Earlier this year, Nutrition Insight met Lubrizol at Vitafoods 2025 to learn about its microencapsulation technology as well as its new curcumin solution for skin radiance. In August, the company expanded its long-standing distribution partnership with India-based Arihant Innochem for its nutraceutical ingredients.

Iron deficiency anemia

In February, the WHO reported that iron deficiency anemia is one of the most prevalent nutritional disorders worldwide, affecting an estimated quarter of the total population (2 billion people), but around 40% of women globally.

Last March, PharmaNutra’s Sucrosomial Iron technology was included in the WHO guidelines to improve global blood health status. Sucrosomial Iron is a patented delivery system designed to protect micronutrient molecules such as iron, increase their absorption, and improve their gastrointestinal tolerability. It is the basis of PharmaNutra’s SiderAL range of iron supplements.

Even for those without anemia, iron deficiency affects many US adults, according to a nationally representative survey of 8,021 US adults in September 2024. The authors call for further studies to determine the optimal absolute screening strategy, as most screening recommendations potentially “miss 70% of iron deficiency cases among children and during pregnancy.”